文献速递免疫规划传染病防控与疫情报告

乌干达HIV感染者新冠疫苗接种率及影响因素

COVID-19 vaccination among people with HIV in Uganda: lessons from a high-risk group with high vaccine uptake for the next pandemic.
PubMed 文献 · Vaccine · 2026-07-10

该研究对乌干达Mbarara地区449名接受抗逆转录病毒治疗的HIV感染者进行横断面二次分析,发现83%(95%CI=75%-92%)报告接种新冠疫苗。未接种者主要因担心副作用(42%)和认为疫苗增加感染风险(16%)而犹豫。未来疫苗宣传应强调安全性和有效性并打击错误信息。

要点

  • HIV感染者新冠疫苗接种率达83%,高于许多高风险群体。
  • 未接种者主要障碍是对疫苗安全性的不信任。
  • 疫苗推广应重点沟通安全性和有效性信息。

核心结论

  • 乌干达接受ART的HIV感染者中新冠疫苗接种率较高,未接种者主要障碍为对疫苗安全性的担忧。

研究设计与样本

  • 横断面二次分析,来自前瞻性队列研究,纳入≥18岁接受ART的HIV感染者449人,2021年12月开始收集数据。

主要发现

  • 83%(95%CI=75%-92%)报告接种新冠疫苗。
  • 未接种者中42%(32/77)因担心副作用,16%(12/77)认为疫苗增加感染风险。
  • 未调整分析中,对COVID-19更担忧、从卫生资源获取信息、ART年限更长、持续获得肥皂和水与接种正相关(p<0.05)。

临床怎么用

  • 针对HIV感染者疫苗推广时应强调疫苗安全性和有效性,并主动纠正错误信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the effectiveness of the COVID-19 vaccine, vaccination rates vary across settings and populations, especially among people living with HIV (PLHIV). We assessed factors associated with COVID-19 vaccination among PLHIV in Mbarara, Uganda. METHODS: We conducted a cross-sectional, secondary analysis of a prospective cohort study consisting of PLHIV ≥18 years old on antiretroviral therapy (ART). We collected data on COVID-19 vaccine uptake and associated factors beginning in December 2021, 9 months after the vaccine became available in Uganda. Reasons for vaccine acceptance and hesitancy were analyzed descriptively, while factors associated with vaccine uptake were assessed using Poisson models with robust standard errors. RESULTS: We analyzed data from 449 participants with a mean age of 46 years (SD 9) and ART duration of 10 years (SD 4). 42% were female, 96% were virally suppressed (<50 copies/mL), and 83% (95% CI = 75%-92%) reported vaccination for COVID-19. In unadjusted analyses, greater concern about COVID-19, obtaining COVID-19 information from health resources, longer ART duration in years, and continuous access to soap and water were positively and significantly correlated with vaccine uptake (p < 0.05). Among those unvaccinated (n = 77/449, 17%), fear of side effects (n = 32/77, 42%) and beliefs that vaccination increased infection risk (n = 12/77, 16%) were predominant reasons for vaccine hesitancy. CONCLUSIONS: We found high rates of COVID-19 vaccination among PLHIV on ART in Uganda. Among those unvaccinated, lack of confidence in the safety of the vaccine was the primary barrier to uptake. Future vaccine campaigns should emphasize vaccine safety and efficacy and actively combat misinformation to promote uptake. REGISTRY NUMBER: Clinical Trials Registration. NCT04066036.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Aung TN, Muyindike W, Hoeppner SS, et al. COVID-19 vaccination among people with HIV in Uganda: lessons from a high-risk group with high vaccine uptake for the next pandemic. Vaccine. 2026. PMID: 42430873. doi:10.1016/j.vaccine.2026.128912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。